PathMD Quizes, Clinical, Hematopathology Coagulation – 02 October 29, 2017 peferguson Make sure to subscribe to PathMD to stay up to date with new content and features!! 1. The diagram shown for this question illustrates initial platelet adhesion and aggregation. The substance highlighted by the red box best represents? Coagulation - Part 2, Case #1GPIIb/IIIaVon Willebrand's factor GPIbFibrinFibrinogen 2. Of extracellular matrix constituents, which is the most important pro-thrombotic component?None of the answers are correctFibronectinCollagenAdhesive gylcoproteins Proteoglycans 3. A young patient is diagnosed with a pulmonary embolism, and is found to have a large DVT. No acquired risk factors for hypercoagability are found, and genetic etiologies are suspected. The patient is still in the ER and has not yet received anticoagulation. Which of the following tests can be performed to evaluate possible hypercoaguable states:PT20210Protein C and S Factor V LeidenFactor V Leiden and PT20210 4. Heparin induced thrombocytopenia is caused by heparin interacting with:HLA receptorsGpIIb/IIIaAnticardiolipin antibodies None of the answers are correctPlatelet factor 4 5. Which of the following has the greatest effect in inhibiting both factors V and VIII?ThrombomodulinThromboplastinFactor XIIIAnti-thrombin III Tissue factor pathway inhibitor 6. All of the following are symptoms of type 1 von Willebrand’s disease EXCEPT:Oral bleeding Joint bleeding EpistaxisEasy bruising 7. The diagram shown for this case represents a platelet control and the patient's platelets is tested for aggregation in the presence of low dose and high-dose ristocetin. In addition, electrophoresis showed decreased large molecular weight von Willebrand's multimers. Mixing the patient's plasma with random donor platelets resulted in the same platelet arrogation findings with high and low dose ristocetin. Based on this information, the best diagnosis is: Coagulation - Part 2, Case #2. Low Dose Ristocetin Control Coagulation - Part 2, Case #2. High Dose Ristocetin Control Coagulation - Part 2, Case #2. Low Dose Ristocetin - PATIENT Coagulation - Part 2, Case #2. High Dose Ristocetin - PATIENTGlanzman's thromboblasthenia Bernard-Soulier syndrome Pseudo-von Willebrand's disease Cannot be determined with the given information von Willebrand's disease, type 2B 8. An acquired inhibitor to factor X can be caused by which of the following?Severe Hemophilia A Severe Hemophilia B Use of bovine thrombin AmyloidosisNone of the answers are correct 9. A 46 y/o woman is found to have a prolonged aPTT with a normal PT. A mixing study was performed, and the aPTT corrected into the high normal range. Clinically, the patient does not have any evidence of bleeding or bleeding tendencies. Further questioning reveals the patient has been noted to have a prolonged aPTT during a routine physical exam 5 years ago. He was referred to a hematologist at that time who told him he was fine and not to worry. Based on these findings, which of the following is the most likely etiology of the patients prolonged aPTT?Factor XII deficiencyFactor IX deficiency (hemophilia B) Factor VIII deficiency (mild hemophilia A) Lupus anticoagulant Factor V inhibitor 10. All of the following may result in a prolonged thrombin clotting time (TCT) EXCEPT:Factor II deficiency HypofibrinogenemiaIncreased fibrin degradation products Heparin contamination Dysfibrinogenemia Loading... Share this: Share on X (Opens in new window) X Share on WhatsApp (Opens in new window) WhatsApp Share on Facebook (Opens in new window) Facebook Email a link to a friend (Opens in new window) Email Print (Opens in new window) Print Share on LinkedIn (Opens in new window) LinkedIn Related